At the news
? BEARISHIMPACT 6/10 424B5 filed Nov 12, 2026 at 08:22 ET
ProKidney Corp. filed a 424B5 prospectus supplement establishing a $200 million at-the-market (ATM) equity facility with Jefferies LLC as sales agent. The company has no approved products, no revenue, and reported $141.9 million in cash as of Q3 2026, with cash runway into mid-2027. The ATM program represents potential dilution of up to 86% of current shares outstanding at the reference price of $1.13 per share, following a $650 million universal shelf filed 14 days earlier.
- ATM facility for up to $200 million of Class A common stock through Jefferies LLC
- Reference price of $1.13 per share (last reported sale on Nov 11, 2026)
- Jefferies receives commission of up to 3.0% of gross proceeds
- At the $1.13 reference price, maximum of 176,991,150 shares could be sold, representing 86% dilution from 205,716,189 shares outstanding as of June 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access